Evidence map›Paper›PMID 27587552›Full record

SynthesisThe European respiratory journal2016

Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method.

Carole D Mitnick, Richard A White, Chunling Lu, Carly A Rodriguez, Jaime Bayona, Mercedes C Becerra, Marcos Burgos, Rosella Centis, Theodore Cohen, Helen Cox and 22 more

Open access · hybridAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The European respiratory journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.American journal of respiratory and critical care medicine · 2019
    Guideline
  2. Trial
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Sputum culture conversion definitions and analytic practices for multidrug-resistant TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2021
    Article
  9. Article
  10. Article
  11. International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2019
    Article
  12. Smoking and pulmonary tuberculosis treatment failure: a case-control study.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2019
    Article
  13. Primary bacillary resistance in multidrug-resistant tuberculosis and predictive factors associated with cure at a referral center in São Paulo, Brazil.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2019
    Article
  14. Article
  15. Journal of clinical medicine · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.The New England journal of medicine · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 20 institutions in 12 countries.

Carole D MitnickDept of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA Partners in Health, Boston, MA, USA carole_mitnick@hms.harvard.edu.
Richard A WhiteDept of Infectious Disease Epidemiology, Norwegian Institute of Public Health, Oslo, Norway Dept of Health Statistics, Norwegian Institute of Public Health, Oslo, Norway.
Chunling LuDept of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA Brigham and Women's Hospital, Division of Global Health Equity, Boston, MA, USA.
Carly A RodriguezDept of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Jaime BayonaSocios en Salud Sucursal, Lima, Peru.
Mercedes C BecerraDept of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA Partners in Health, Boston, MA, USA Brigham and Women's Hospital, Division of Global Health Equity, Boston, MA, USA.
Marcos BurgosDept of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Rosella CentisWHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy.
Theodore CohenEpidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Helen CoxMédecins Sans Frontières, Cape Town, South Africa.
Lia D'AmbrosioWHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy Public Health Consulting Group, Lugano, Switzerland.
Manfred DanilovitzTartu University Hospital, Lung Clinic, Tartu, Estonia.
Dennis FalzonGlobal TB Programme, World Health Organization, Geneva, Switzerland.
Irina Y GelmanovaPartners in Health Russia, Moscow, Russia.
Maria T GlerMakati Medical Center, Manila, Philippines.
Jennifer A GrinsdaleTuberculosis Control, San Francisco Department of Public Health, San Francisco, CA, USA.
Timothy H HoltzUS Centers for Disease Control and Prevention, Atlanta, GA, USA.
Salmaan KeshavjeeDept of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA Partners in Health, Boston, MA, USA Brigham and Women's Hospital, Division of Global Health Equity, Boston, MA, USA.
Vaira LeimaneState Agency for Tuberculosis and Lung Diseases (TPSVA), Riga, Latvia.
Dick MenziesMontreal Chest Institute, McGill University, Montreal, QC, Canada.
Giovanni Battista MiglioriWHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy.ORCID 0000-0002-2597-574X
Meredith B MilsteinDept of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA Bouvé College of Health Sciences, Northeastern University, Boston, MA, USA.
Sergey P MishustinTomsk TB and Pulmonary Medical Center, Tomsk Oblast, Russia.
Marcello PaganoDept of Biostatistics, Harvard School of Public Health, Boston, MA, USA.
Maria I QuelapioTropical Disease Foundation, Philippine Institute of Tuberculosis, Makati City, Philippines.
Karen SheanLung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, Dept of Medicine, University of Cape Town, Cape Town, South Africa.
Sonya S ShinDept of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA Partners in Health, Boston, MA, USA Brigham and Women's Hospital, Division of Global Health Equity, Boston, MA, USA Socios en Salud Sucursal, Lima, Peru.
Arielle W TolmanDept of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Martha L van der WaltSouth African Medical Research Council, Tuberculosis Research Platform, Pretoria, South Africa.
Armand Van DeunInstitute of Tropical Medicine, Antwerp, Belgium.
Piret ViikleppNational Institute for Heath Development, Tallinn, Estonia.
Collaborative Group for Analysis of Bacteriology Data in MDR-TB Treatment
Brigham and Women's Hospital · USFondazione Salvatore Maugeri · ITHarvard University · USCenters for Disease Control and Prevention · USEsSALUD · PEInstituut voor Tropische Geneeskunde · BEMakati Medical Center · PHMcGill University · CAMédecins Sans Frontières · ZANational Institute for Health Development · EENortheastern University · USNorwegian Institute of Public Health · NOPartners In Health · USSan Francisco Department of Public Health · USSouth African Medical Research Council · ZAState Education Development Agency · LVTartu University Hospital · EETomsk National Research Medical Center · RUTropical Disease Foundation · PHUniversity of Cape Town · ZA

Funding

Molecular epidemiology of drug-resistant tuberculosis in PeruK01HL080939 · NHLBI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BECERRA, MERCEDES C · 2005 to 2009
$680k
Clinical Outcomes Research in MDR-TBK01AI065836 · NIAID · HARVARD MEDICAL SCHOOL · PI MITNICK, CAROLE D. · 2006 to 2008
$346k
NHLBI NIH HHS K01 HL080939NIAID NIH HHS K01 AI065836
6 · The paper itself

Abstract

Debate persists about monitoring method (culture or smear) and interval (monthly or less frequently) during treatment for multidrug-resistant tuberculosis (MDR-TB). We analysed existing data and estimated the effect of monitoring strategies on timing of failure detection.We identified studies reporting microbiological response to MDR-TB treatment and solicited individual patient data from authors. Frailty survival models were used to estimate pooled relative risk of failure detection in the last 12 months of treatment; hazard of failure using monthly culture was the reference.Data were obtained for 5410 patients across 12 observational studies. During the last 12 months of treatment, failure detection occurred in a median of 3 months by monthly culture; failure detection was delayed by 2, 7, and 9 months relying on bimonthly culture, monthly smear and bimonthly smear, respectively. Risk (95% CI) of failure detection delay resulting from monthly smear relative to culture is 0.38 (0.34-0.42) for all patients and 0.33 (0.25-0.42) for HIV-co-infected patients.Failure detection is delayed by reducing the sensitivity and frequency of the monitoring method. Monthly monitoring of sputum cultures from patients receiving MDR-TB treatment is recommended. Expanded laboratory capacity is needed for high-quality culture, and for smear microscopy and rapid molecular tests.

Indexed as

AdultAntitubercular AgentsCohort StudiesCoinfectionFemaleHumansKaplan-Meier EstimateMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisProportional Hazards ModelsRiskSputumTreatment FailureTuberculosis, Multidrug-ResistantAntitubercular Agents

Identifiers

PMID27587552
PMCPMC5045442
OpenAlexW2511705938

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.